Epicrispr's EPI-321 FSHD readout pushed to July 2027 as trial closes enrollment
The gene therapy's primary completion date moved five years earlier on paper, from March 2031 to July 2027, as the 12-patient first-in-human study stops recruiting with early safety and muscle-volume signals already in hand.
Executive Summary
- Epicrispr pulled forward the primary completion date on its first-in-human Phase 1/2 trial of EPI-321 in FSHD by several years, aligning the registered readout window with a study that has already stopped recruiting.
- The sponsor has disclosed interim safety and biomarker data from the dose-escalation cohort showing no serious adverse events and early signs of increased muscle volume, so the pending completion date will extend and confirm that early signal rather than introduce it.
- EPI-321 is one of two DUX4-directed programs in FSHD Type 1 in clinical testing, with Arrowhead Pharmaceuticals' RNA-based ARO-DUX4 running as the direct comparator and closer to its own primary completion.
- The trial's enrollment held flat at its target and the status change to Active, not recruiting is the routine consequence of enrollment closing, not a sign of distress.
The registry change
Epicrispr Biotechnologies, Inc. amended the primary completion date for NCT06907875, its first-in-human study of EPI-321 in FSHD Type 1, from March 31, 2031 to July 7, 2027, according to the trial record. The same July 20, 2026 update also flipped the trial's status from Recruiting to Active, not recruiting. The trial is a Phase 1/2, open-label, non-randomized study of an intravenous AAV gene therapy targeting DUX4 expression, with a target enrollment of 12 adults with genetically confirmed FSHD Type 1. NCT06907875A First-in-human Study of EPI-321 in Facioscapulohumeral Muscular DystrophyNCT06907875
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
What the trial will test
The registered primary endpoint is the frequency of adverse events and treatment-related adverse reactions through up to five years of follow-up, making this a safety and tolerability readout rather than an efficacy trial in the traditional sense. Secondary endpoints track DUX4 expression, EPI-321 cargo transcriptional activity, D4Z4 methylation status, and vector copy number in skeletal muscle biopsies at baseline, three, and twelve months. Enrollment grew from 9 to 12 patients between the trial's initial submissions and December 2025, a change the operational model classifies within the routine band for a Phase 1/2 first-in-human design. NCT06907875A First-in-human Study of EPI-321 in Facioscapulohumeral Muscular DystrophyNCT06907875
What's already on record
Epicrispr has already reported interim data from the dose-escalation cohort: a statistically significant increase in whole-body lean muscle volume by MRI and biomarker changes consistent with DUX4 suppression, alongside no serious adverse events. A separate disclosure describes the same interim readout as showing favorable efficacy and tolerability with gains sustained six months after treatment. The pulled-forward completion date lines up the registered study window with a program that has already produced a hypothesis-generating safety and biomarker signal in a small, open-label cohort; the July 2027 date will extend that observation across the full 12-patient dosing set rather than introduce a first look. NCT06907875+1A First-in-human Study of EPI-321 in Facioscapulohumeral Muscular DystrophyNCT06907875A First-in-human Study of EPI-321 in Facioscapulohumeral Muscular DystrophyJul 20, 2026
Regulatory backdrop
EPI-321 holds FDA Fast Track, Orphan Drug, and Rare Pediatric Disease designations for FSHD, first granted in March 2025 and reaffirmed in March 2026. These designations reflect the rare-disease and unmet-need status of FSHD and support expedited review pathways; they do not by themselves indicate how the trial's safety data will read out. NCT06907875A First-in-human Study of EPI-321 in Facioscapulohumeral Muscular DystrophyNCT06907875
Competitive position
DUX4-directed programs in FSHD Type 1 remain sparse: EPI-321 and Arrowhead Pharmaceuticals' ARO-DUX4 are the only two industry trials targeting DUX4 in this indication currently in clinical testing, and they diverge in modality, EPI-321 is a gene therapy delivered intravenously, while ARO-DUX4 is an RNA interference therapeutic. Arrowhead's Phase 1/2 study of ARO-DUX4, NCT06131983, is nearing its own primary completion in December 2026, tracking adverse events through end of study, which puts a second DUX4-targeting safety readout ahead of Epicrispr's on the calendar. Avidity Biosciences' AOC 1020, an RNA-based FSHD program, has advanced into a Phase 3 study with a target completion in 2028, giving the broader FSHD field a later-stage precedent even though it does not share EPI-321's DUX4 target directly. NCT06907875A First-in-human Study of EPI-321 in Facioscapulohumeral Muscular DystrophyNCT06907875
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.